BCG immunotherapy for carcinoma of the urinary bladder.
Treatment of superficial bladder cancer using BCG as an immunotherapeutic agent has proved effective. Stringent safety procedures have been introduced at Yeovil District Hospital so that this treatment is available to patients with bladder cancer, while ensuring that other patients and staff are protected from the possibility of BCG cross-infection.
Cumisky
S
S
Yeovil District Hospital.
D000818:Animals; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002417:Cattle; D003428:Cross Infection / Q000209:etiology / Q000517:prevention & control; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing / Q000592:standards; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D017053:Infection Control / Q000379:methods; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D014380:Tuberculosis, Bovine / Q000209:etiology / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000451:nursing
D001500:BCG Vaccine